{
    "2020-12-02": [
        [
            {
                "time": "",
                "orginal_text": "格隆汇港股聚焦(12.2)︱中国奥园前11月合约销售额升12%至1137.6亿元；东风集团股份与交通银行、武汉经济技术开发区签署协议赋能产业发展",
                "features": {
                    "keywords": [
                        "中国奥园",
                        "合约销售额",
                        "东风集团",
                        "交通银行",
                        "武汉经济技术开发区"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "房地产",
                        "汽车",
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "orginal_text": "【安信中小盘】立方制药、恒玄科技、航亚科技-次新股资讯1202",
                "features": {
                    "keywords": [
                        "立方制药",
                        "恒玄科技",
                        "航亚科技"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "科技"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "orginal_text": "上海医药(02607)：盐酸贝那普利片及盐酸度洛西汀肠溶胶囊通过仿制药一致性评价",
                "features": {
                    "keywords": [
                        "上海医药",
                        "盐酸贝那普利片",
                        "盐酸度洛西汀肠溶胶囊",
                        "仿制药一致性评价"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "恒指收跌0.13% 林业及木材板块领跌",
                "features": {
                    "keywords": [
                        "恒指",
                        "林业",
                        "木材板块"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "林业",
                        "木材"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "orginal_text": "上海医药(601607.SH)：盐酸贝那普利片及盐酸度洛西汀肠溶胶囊通过仿制药一致性评价",
                "features": {
                    "keywords": [
                        "上海医药",
                        "盐酸贝那普利片",
                        "盐酸度洛西汀肠溶胶囊",
                        "仿制药一致性评价"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "交银：关注研发实力强及估值偏低的药企 如康方生物",
                "features": {
                    "keywords": [
                        "交银",
                        "研发实力",
                        "估值偏低",
                        "康方生物"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}